Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).
HSV Infection
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35205
University Arizona - Department of Medicine Arizona Health Sciences Center, Tucson, Arizona, United States, 85724
City of Hope, Duarte, California, United States, 91010
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
University of California, Division of Infectious Diseases, Sacramento, California, United States, 95817
Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States, 32720
Midway Immunology and Research Center (MIRC), Fort Pierce, Florida, United States, 34982
University of Florida (UF) - Division of Infectious Disease, Gainesville, Florida, United States, 32610
Links Clinical Trials, Miami, Florida, United States, 33176
Emory Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States, 30308
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
16 Years to
ALL
No
AiCuris Anti-infective Cures AG,
2025-04